Physician profile
Bailey Yee
NPI 1073194221
$987.42
in general payments reported to CMS, 2019-2025
14 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $346 · 2023: $93.20 · 2024: $304 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $459.27 | 2022-2025 | Eysuvis, Rocklatan, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $149.68 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $67.52 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $59.87 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $45.30 | 2022 | |
| Rxsight INC | $44.47 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Sight Sciences, INC. | $25.80 | 2022 | |
| Apellis Pharmaceuticals, INC. | $22.76 | 2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $22.05 | 2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Dompe US, INC. | $21.04 | 2025 | Oxervate |
| Biotissue Holdings INC. | $19.25 | 2025 | |
| Coherus Oncology, INC. | $18.93 | 2023 | |
| Abbvie INC. | $16.45 | 2024 | |
| Thea Pharma INC. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.